Log in

NASDAQ:MGNX - MacroGenics Stock Price, Forecast & News

$5.82
-0.21 (-3.48 %)
(As of 03/27/2020 04:00 PM ET)
Today's Range
$5.60
Now: $5.82
$6.16
50-Day Range
$4.27
MA: $8.26
$12.01
52-Week Range
$4.04
Now: $5.82
$19.80
Volume341,597 shs
Average Volume521,575 shs
Market Capitalization$285.94 million
P/E RatioN/A
Dividend YieldN/A
Beta2.13
MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets HER2-expressing tumors, such as various breast and gastroesophageal cancers. The company is also developing Flotetuzumab, a DART molecule that recognizes CD123 and CD3; MGA012, an anti-PD-1 monoclonal antibody, which inhibits programmed cell death protein 1 (PD-1); MGD013, a monoclonal antibody that targets the immune checkpoints PD-1 and lymphocyte-activation gene 3; MGD019, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; and Enoblituzumab, a monoclonal antibody that targets B7-H3. In addition, the company is developing MGD009, a DART molecule that targets B7-H3 expressed on tumor cells and CD3; MGC018, an antibody drug conjugate, which targets solid tumors expressing B7-H3; and MGD007, a DART molecule, which targets glycoprotein A33 and CD3; and MGD014, a DART molecule that targets virus-infected cells. It has strategic collaborations with Incyte Corporation; Les Laboratoires Servier and Institut de Recherches Servier; and Zai Lab Limited. MacroGenics, Inc. was founded in 2000 and is headquartered in Rockville, Maryland.
Read More
MacroGenics logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MGNX
CUSIPN/A
Phone301-251-5172

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$64.19 million
Book Value$4.71 per share

Profitability

Net Income$-151,810,000.00
Net Margins-236.51%

Miscellaneous

Employees364
Market Cap$285.94 million
Next Earnings Date5/6/2020 (Estimated)
OptionableOptionable

Receive MGNX News and Ratings via Email

Sign-up to receive the latest news and ratings for MGNX and its competitors with MarketBeat's FREE daily newsletter.


MacroGenics (NASDAQ:MGNX) Frequently Asked Questions

How has MacroGenics' stock been impacted by COVID-19 (Coronavirus)?

MacroGenics' stock was trading at $6.49 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MGNX shares have decreased by 10.3% and is now trading at $5.82. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of MacroGenics?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MacroGenics in the last year. There are currently 1 sell rating, 1 hold rating and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for MacroGenics.

When is MacroGenics' next earnings date?

MacroGenics is scheduled to release its next quarterly earnings announcement on Wednesday, May 6th 2020. View our earnings forecast for MacroGenics.

How were MacroGenics' earnings last quarter?

MacroGenics Inc (NASDAQ:MGNX) posted its quarterly earnings results on Tuesday, February, 25th. The biopharmaceutical company reported ($0.61) EPS for the quarter, topping analysts' consensus estimates of ($0.71) by $0.10. The biopharmaceutical company earned $25.19 million during the quarter, compared to analyst estimates of $10.74 million. MacroGenics had a negative net margin of 236.51% and a negative return on equity of 55.16%. View MacroGenics' earnings history.

What price target have analysts set for MGNX?

12 Wall Street analysts have issued 1 year target prices for MacroGenics' stock. Their forecasts range from $6.00 to $50.00. On average, they anticipate MacroGenics' stock price to reach $18.91 in the next twelve months. This suggests a possible upside of 224.9% from the stock's current price. View analysts' price targets for MacroGenics.

Has MacroGenics been receiving favorable news coverage?

News headlines about MGNX stock have been trending extremely positive on Saturday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. MacroGenics earned a coverage optimism score of 5.0 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the immediate future. View the latest news aboutMacroGenics.

Are investors shorting MacroGenics?

MacroGenics saw a decrease in short interest in February. As of February 28th, there was short interest totaling 3,670,000 shares, a decrease of 5.2% from the February 13th total of 3,870,000 shares. Based on an average daily volume of 486,000 shares, the short-interest ratio is currently 7.6 days. Approximately 8.5% of the company's shares are sold short. View MacroGenics' Current Options Chain.

Who are some of MacroGenics' key competitors?

What other stocks do shareholders of MacroGenics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MacroGenics investors own include AbbVie (ABBV), Exelixis (EXEL), Sangamo Therapeutics (SGMO), Gilead Sciences (GILD), NVIDIA (NVDA), TherapeuticsMD (TXMD), Incyte (INCY), Karyopharm Therapeutics (KPTI), Nektar Therapeutics (NKTR) and TG Therapeutics (TGTX).

Who are MacroGenics' key executives?

MacroGenics' management team includes the following people:
  • Dr. Scott Koenig, CEO, Pres & Director (Age 67)
  • Mr. James Karrels, Sr. VP, CFO & Sec. (Age 52)
  • Dr. Ezio Bonvini, Sr. VP of Research & Chief Scientific Officer (Age 65)
  • Mr. Eric Blasius Risser, Sr. VP of Bus. Devel. & Portfolio Management and Chief Bus. Officer (Age 46)
  • Dr. Jon M. Wigginton, Sr. VP of Clinical Devel. & Chief Medical Officer (Age 57)

What is MacroGenics' stock symbol?

MacroGenics trades on the NASDAQ under the ticker symbol "MGNX."

Who are MacroGenics' major shareholders?

MacroGenics' stock is owned by a number of institutional and retail investors. Top institutional investors include State Street Corp (3.94%), Sofinnova Investments Inc. (2.40%), Rhenman & Partners Asset Management AB (2.17%), Pinnacle Associates Ltd. (1.75%), FMR LLC (1.70%) and Candriam Luxembourg S.C.A. (1.53%). Company insiders that own MacroGenics stock include Eric Blasius Risser, Jeffrey Stuart Peters, Matthew K Fust and Thomas Spitznagel. View institutional ownership trends for MacroGenics.

Which major investors are selling MacroGenics stock?

MGNX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, UBS Group AG, Rafferty Asset Management LLC, Jefferies Group LLC, Spark Investment Management LLC, Massachusetts Financial Services Co. MA, Citigroup Inc., and New York State Common Retirement Fund. View insider buying and selling activity for MacroGenics.

Which major investors are buying MacroGenics stock?

MGNX stock was acquired by a variety of institutional investors in the last quarter, including Sofinnova Investments Inc., Pinnacle Associates Ltd., Rhenman & Partners Asset Management AB, Panagora Asset Management Inc., Oxford Asset Management LLP, Geode Capital Management LLC, Principal Financial Group Inc., and Amia Capital LLP. View insider buying and selling activity for MacroGenics.

How do I buy shares of MacroGenics?

Shares of MGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is MacroGenics' stock price today?

One share of MGNX stock can currently be purchased for approximately $5.82.

How big of a company is MacroGenics?

MacroGenics has a market capitalization of $285.94 million and generates $64.19 million in revenue each year. The biopharmaceutical company earns $-151,810,000.00 in net income (profit) each year or ($3.16) on an earnings per share basis. MacroGenics employs 364 workers across the globe. View additional information about MacroGenics.

What is MacroGenics' official website?

The official website for MacroGenics is http://www.macquarie.com/.

How can I contact MacroGenics?

MacroGenics' mailing address is 9704 MEDICAL CENTER DRIVE, Rockville MD, 20850. The biopharmaceutical company can be reached via phone at 301-251-5172.


MarketBeat Community Rating for MacroGenics (NASDAQ MGNX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  346 (Vote Outperform)
Underperform Votes:  359 (Vote Underperform)
Total Votes:  705
MarketBeat's community ratings are surveys of what our community members think about MacroGenics and other stocks. Vote "Outperform" if you believe MGNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MGNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/28/2020 by MarketBeat.com Staff

Featured Article: What is systematic risk?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel